Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS.
Im SA, et al. Among authors: kim sb, kim wk, kim ty, kim kw.
Oncol Rep. 2005 Aug;14(2):481-7.
Oncol Rep. 2005.
PMID: 16012734
Clinical Trial.